Multiple Myeloma Drugs Global Market By Drug Class, By Distribution Channel, By Disease Type, By End User, Opportunity Analysis and Forecast, 2024-2033 | Pfizer Inc., Bayer AG, Novartis AG, Sanofi SA, AstraZeneca PLC

The Multiple Myeloma Drugs Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Multiple Myeloma Drugs Market:
https://www.thebusinessresearchcompany.com/report/multiple-myeloma-drugs-global-market-report

According to The Business Research Company’s Multiple Myeloma Drugs Global Market Report 2024, The multiple myeloma drugs market size has grown strongly in recent years. It will grow from $20.7 billion in 2023 to $22.09 billion in 2024 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to improved diagnosis, clinical trials success, understanding disease biology, healthcare infrastructure improvements, patient advocacy and awareness.

The multiple myeloma drugs market size is expected to see strong growth in the next few years. It will grow to $28.07 billion in 2028 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to immunotherapy innovations, targeted therapies expansion, liquid biopsy applications, emergence of car-t cell therapy, biomarker discovery. Major trends in the forecast period include long-term survivorship focus, exploration of epigenetic therapies, expanded role of telemedicine, expanded access to novel therapies, sustainability in myeloma care:.

The increasing prevalence of hematological cancer is expected to drive the growth of the multiple myeloma drugs market going forward. Hematological cancers start in blood-forming tissue, such as bone marrow, or immune system cells, such as leukemia, lymphoma, multiple myeloma, and others. Multiple myeloma medications are often used to treat various myeloma by killing and limiting the growth of cancer cells by decreasing the process of cell division by stimulating numerous enzymatic actions and assisting bones to stay strong and reducing pain in the weakening bone. For instance, in January 2023, according to the American Cancer Society (ACS), a US-based health organization dedicated to eliminating cancer, there were approximately 59,610 newly diagnosed cases of leukemia and around 20,380 cases of acute myeloid leukemia (AML). Additionally, the total number of deaths attributed to leukemia amounted to 23,710. Therefore, the increasing prevalence of hematological cancer is driving the growth of multiple myeloma drugs market.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=11943&type=smp

The multiple myeloma drugs market covered in this report is segmented –
1) By Drug Type: Immunomodulatory Drugs, Proteasome Inhibitors, Histone Deacetylase Inhibitors, Monoclonal Antibody Drugs, Steroids, Other Drug Types
2) By Therapy: Targeted Therapy, Biologic Therapy, Chemotherapy, Other Therapies
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
4) By End-User: Men, Women

Product innovation is a key trend gaining popularity in the multiple myeloma drugs market. Major companies operating in the multiple myeloma drugs market are focused on developing innovative products to strengthen their position and gain a competitive advantage. For instance, in March 2022, Janssen Biotech Inc., a Japan-based biotechnology company, received the United States Food and Drug Administration approval for Carvykti, a CAR T-Cell therapy (personalized immunotherapy) for multiple myeloma. CARVYKTI (ciltacabtagene autoleucel) is a genetically modified autologous cell-based product composed of T cells transduced ex vivo with a replication-incompetent lentiviral vector encoding an anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) consisting of two single domain antibodies linked to a 4-1BB costimulatory domain and a CD3-zeta signaling domain. Patients who have received four or more lines of therapy, including treatment with three critical kinds of multiple myeloma medications (an immunomodulating agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody), are eligible to receive it to treat relapsed conditions.

The multiple myeloma drugs market report table of contents includes:
1. Executive Summary